Semaglutide plateau: why weight “freezes” and what the studies show

In brief: what is a “plateau” in weight loss with semaglutide?

A “plateau” means that the rate of weight loss visibly slows or stops for weeks, and sometimes for months — even though habits, dosing or activity have not changed significantly. This phenomenon is normal with almost all weight-loss strategies (diet, medication, GLP-1 agonists, bariatric surgery). It is a consequence of both biological adaptation (the body “saves” energy) and behavioural factors (small deviations that accumulate).

It is important to distinguish a “true plateau” from a natural slowing of the weight-loss curve. In the large STEP trials with semaglutide, the mean weight reduction was cumulative during the first ~12-15 months, after which the curve became flatter, but the benefits were maintained with continued treatment. In STEP-1, the mean change in weight up to week 68 was -14.9% versus -2.4% with placebo, indicating a strong effect, but the rate understandably slowed towards the end of the period. In STEP-5 (104 weeks), the reduction was maintained at around -15.2% with continued treatment, confirming that a “plateau” is often a new equilibrium and not a failure.

Why does a plateau occur? (biological and behavioural reasons)

1. Adaptive thermogenesis (metabolic adaptation). During weight loss, the body reduces energy expenditure more than lean-mass loss would predict. This is a proven mechanism behind the plateau and the tendency of weight to “regain”.

2. Less “hidden energy expenditure” (NEAT). Involuntary movement during the day (gestures, walking, fidgeting) reduces the calorie deficit. The body “saves” energy, which lowers total daily expenditure.

3. Dosing that works but has stabilised. Semaglutide is long-acting (t½ ~ 1 week), reaches steady-state concentration in ~4–5 weeks and maintains a stable pharmacological effect with weekly administration. This means that after titration, the effect becomes predictable and the rate of reduction naturally decreases as the “readily available” stores are depleted.

4. Tolerance/tolerability and real-world use. Gastrointestinal problems can limit reaching or maintaining a maintenance dose, and interruptions (delayed injections, missed doses) “dilute” the effect.

5. “Protection” of the set point/biological weight. The body seeks a new equilibrium at a lower weight. Appetite control improves with GLP-1, but opposing signals from other hormones increase over time - the result is slower subsequent progress.

6. Diabetes, comorbidities and medicines. In T2D, weight loss is on average more modest. Some medicines (e.g. steroids) act “against” weight loss.

7. Hydration, glycogen and cyclical retention. Day-to-day fluctuations (salt, cycle, stress) can “mask” the real trend for 2-4 weeks.

8. Behavioural “micro-slips”. After months of success, small additions (calorie-containing drinks, side dishes, frequency of “snacks”) bring the energy balance back to almost zero — without any subjective feeling of change.

What do the clinical data say about the plateau on semaglutide?

• STEP-1 (NEJM): Mean reduction of −14.9% at 68 weeks; progresses steadily, but with a reasonable slowing towards the end — a typical “flattening” of the curve, not an abrupt stop.

• STEP-5 (2 years): With continued semaglutide plus behavioural support, the result was maintained for up to 104 weeks (-15.2% on average), which means that the “plateau” was more a stable lower weight as treatment continued.

• STEP-4 (randomised withdrawal): After a 20-week period with a reduction of ~-10.6%, participants who continued semaglutide lost a further −7.9% by week 68. Those who stopped regained +6.9% over the same period - a clear message that discontinuation often leads to a “reverse slope” and not to a plateau.

• STEP-1 (extension after discontinuation): About 2/3 of the lost weight is regained within 1 year of stopping (without active support) and some of the cardiometabolic benefits also return to baseline levels. This is not a “plateau”, but physiological recovery in the absence of treatment.

Conclusion: When semaglutide is continued, the mean curve shows sustainable results and a slower but continuous reduction or maintenance. The “plateau” is most often an expected slowing plus metabolic adaptation—not a failure of the GLP-1 mechanism.

Warning: This text is intended for educational purposes only and does not replace medical advice. Decisions about treatment/dosing should be made with a healthcare professional.

---

Frequently asked questions (FAQ)

1) Is the plateau normal with semaglutide?

Yes. Large trials show a strong mean reduction and a natural slowing at 12-15 months. This is expected and does not mean the medicine has “stopped” working.

2) What do the studies show after semaglutide is stopped?

In STEP-4, participants who stopped regained +6.9% by week 68, and in the STEP-1 extension about 2/3 of the lost weight was regained within 1 year. So the studies describe partial weight regain after discontinuation, not a plateau.

3) Why do some people lose less weight?

Individual differences (age, sex, starting weight, type 2 diabetes, medication, sleep/stress) and metabolic adaptation. This is characteristic of all weight interventions.

4) Are there scientific approaches to “shifting” the plateau?

Combinations (e.g. amylin + semaglutide) are under development and have shown greater reduction in trials (REDEFINE programme).

5) How long does semaglutide “stay” in the body?

Because of a half-life of about one week and strong binding to albumin, the medicine remains in the bloodstream for weeks after the dose is given. Steady state is reached after about 4-5 weeks.

Sources

• STEP-1 (NEJM): −14.9% at 68 weeks.

• STEP-5 (Nature Medicine): maintenance of ~−15% up to 104 weeks with continuation.

• STEP-4 (JAMA): after the initial phase, those who continued lost a further −7.9%, those who stopped gained +6.9% (20→68 weeks).

• STEP-1 extension: ~ 2/3 regain within 1 year after discontinuation.

• Adaptive thermogenesis and the plateau: overview/guidelines.

• Pharmacokinetics (EMA): t½ ~ 1 week; steady state at 4–5 weeks.

• Combinations under development (amylin + semaglutide).